EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

27. How can a clinic switch GLP-1 pharmacy partners without disrupting treatment?

Dose Diligence research deskSection 01 · Page 27 of 34Last updated 17 Nov 2026

Transition by patient status and next supply need, not by sending every prescription to a new destination at once. Clinical decisions, prescription changes and operational reconciliation need separate owners.

Proposed transition sequence:

  1. Map the population: current product, presentation, state, last fill, expected next need and unresolved order status.
  2. Verify the destination: permissions, product acceptance, capacity and payment route.
  3. Assign clinical review: formulation, medicine or regimen changes go to the prescriber.
  4. Reconcile existing orders: distinguish prescriptions awaiting action, paid orders, shipped parcels, refunds and unused refills.
  5. Communicate costs and actions: tell patients who will contact them and what they must do.
  6. Pilot a bounded cohort: include both straightforward and exception-prone workflows.
  7. Expand only after reconciliation: confirm receipt and resolve duplicate billing or shipment risks.
  8. Retain transition support: do not terminate access to necessary records prematurely.

Lilly’s FAQ states that changes in medicine, dose or formulation require a new prescription in its workflow. Do not treat a pharmacy migration as permission for an administrative product substitution. (lilly.com)

Define stop conditions before launch: unexplained concentration differences, unresolved permissions, missing instructions or untraceable orders should halt the affected transition.

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
Section sources →